
Immunocore names chief executive
pharmafile | January 14, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Eliot Forster, immunocoreÂ
Oxford-based biotec Immunocore has announced the appointment of Dr Eliot Forster as its chief executive with immediate effect.
Forster takes almost 25 years of industry experience to the role and joins from European biotech Creabilis, where he has served as its chief executive since 2010. Prior to joining Creabilis he was chief executive of US firm Solace Pharmaceuticals.
His other previous roles include positions at Pfizer where he was responsible for activities across multiple geographies, and prior to that Forster worked at GlaxoSmithKline. He is currently chairman of the MedCity project, launched in April 2014 to grow a life sciences cluster in London and the greater south east, and will continue in that role.
Forster succeeds James Noble who is the founding chief executive of Immunocore and its sister company, Adaptimmune. Noble stood down in this role in March last year to become full-time chief executive of Adaptimmune and remains a non-executive director of Immunocore.
Noble says: “I am very pleased to hand the baton over to Eliot and I wish him every success with taking the company forward.”
Forster adds: “Through substantial scientific achievement, the company has created an innovative and robust platform technology to tackle cancer and viral disease, and I look forward to working together with the team to build one of Europe’s premier biotechnology companies.”
Related Content

AstraZeneca loses two senior executives as biotechs appoint new CEOs
Two of AstraZeneca’s senior executives have been poached by the biotech firms Ironwood Pharmaceuticals and …

Lilly and Immunocore collaborate on melanoma
Eli Lilly is teaming up again with UK biotech Immunocore in order to work together …

AstraZeneca signs immuno-oncology deal with UK firm
UK pharma and biotech firms AstraZeneca and Immunocore are teaming up to launch early-stage studies …






